<DOC>
	<DOCNO>NCT02380625</DOCNO>
	<brief_summary>The purpose study determine whether multiple therapeutic regimen effective treatment Ebola Virus Disease ( EVD )</brief_summary>
	<brief_title>Multiple Treatments Ebola Virus Disease ( EVD )</brief_title>
	<detailed_description>The ongoing epidemic EVD ravage part West Africa , initial case report December 2013 . There license specific therapy disease , case-fatality rate approximately 50-70 % . Although anecdotal clinical data , recent study animal model , vitro screen suggest treatment EVD patient anti-viral agent , immune modifying agent , and/or convalescent blood product may effective , evaluate clinical trial . This multi-arm clinical trial evaluate efficacy safety multiple regimen , mono-therapy combination therapy . Provision regimen , find effective safe , would major impact current future epidemic provide effective treatment option . As described previous adaptive trial , randomization probability treatment regimen create base 14-day mortality , use weight randomization subsequently enrol participant . Participants continually preferentially assign regimen well initial performance . New agent add exist agent remove trial evolves .</detailed_description>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Hemorrhagic Fever , Ebola</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<criteria>Males female age 6 month &gt; 8kg weight Confirmed case EVD Admission hospital &lt; 48 hour prior enrollment Participant family member/guardian able willing provide sign informed consent Prior treatment specific experimental antiEVD product , expectation receive another experimental antiEVD product course study ( include general supportive care nutritional supplement routinely administer hospitalized patient EVD ) Unresponsive In treat physician opinion , inability comply study treatment regimen</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Ebola</keyword>
	<keyword>EVD</keyword>
	<keyword>Adaptive design</keyword>
	<keyword>therapeutic</keyword>
</DOC>